Summary ASX-200 medical imaging player Pro Medicus enters in an agreement with Intermountain Healthcare to implement Visage 7 technology. The Intermountain deal represents the fifth major contract secured by Pro Medicus in the last six months. ...
On 14 January 2021, Orthocell Limited (ASX:OCC) has announced that it has been granted FDA 510(k) clearance to go ahead with its CelGro collagen medical device's supply and marketing. The company plans to use the device in the procedures related to...
Some Australian scientists are proposing to delay mass inoculation using AstraZeneca’s COVID-19 vaccine over the lower efficiency of the vaccine as compared to the one developed by Pfizer and its partner BioNTech. Image Source: © Kalkin...
Summary Drug development company Acrux Limited has got the green light from the US FDA for its generic product, equivalent to Testosterone Topical Solution from Perrigo. The Company can now produce and market the generic drug. The topical drug...
Summary Nedlands-headquartered Creso Pharma delivers the 2nd shipment of its cannaQIX® products to Pharma Dynamics in South Africa. With a second purchase order (PO) and delivery, Creso adds A$320K to its growing revenue. The cannabis play...
Summary AVITA Medical highlighted its anticipated revenue and other commercial metrics for the second quarter of 2021. US-based RECELL revenue increased by 62% and total global revenue by 57% over the same quarter in the prior year. During the...
Summary Market is reacting adversely to the trading update provided by PolyNovo for H1 FY21. The company said first-half FY21 sales were 31% higher compared to H1 FY20. PolyNovo Limited (ASX:PNV) has reported a trading update f...
ECS Botanics Holdings Ltd (ASX:ECS) on Tuesday announced that it would acquire Victoria-based Murray Meds, an advanced medicinal cannabis cultivator. The company signed a binding Term Sheet agreement with Flowerday Holdings Pty Ltd to acquire 100 p...
Summary 2020 was a mixed bag for CSL Limited. However, the last few months have been challenging for the ASX 200 biotech player. The Company has experienced a reduced volume of plasma collections due to the COVID-19 pandemic-induced restriction...
Summary ASX-200 Mesoblast Limited disclosed some additional results Phase 3 trial of REVASCOR® in CHF patients. The significant findings may indicate a breakthrough to address the principal unmet needs in CHF. With the positive findings, M...
Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)